主要股东
注:以下部分股东代表特定权益共同体,直接或间接持有上市公司股份
| 序号 | 股东名称 | 是否机构 | 持股数(股) | 持股比例 | 持股变动数(股) | 持股数变动比例 | 投票权比例 |
|---|---|---|---|---|---|---|---|
| 1 | Edward Mathers | 否 | 1515.48万 | 23.73% |
|
|
-- |
| 2 | Entities affiliated with New Enterprise Associates | 是 | 1507.69万 | 23.64% | 新增 | 新增 | -- |
| 3 | Entities affiliated with Frazier Life Sciences | 是 | 666.36万 | 11.09% | 新增 | 新增 | -- |
| 4 | Entities affiliated with Venrock Healthcare Capital Partners | 是 | 632.84万 | 9.99% | 新增 | 新增 | -- |
| 5 | Entities affiliated with Viking Global Investors LP | 是 | 617.86万 | 9.99% | 新增 | 新增 | -- |
| 6 | Entities affiliated with Fairmount Funds Management LLC | 是 | 603.47万 | 9.99% | 新增 | 新增 | -- |
| 7 | Entities affiliated with Rubric Capital Management LP | 是 | 568.44万 | 9.46% | 新增 | 新增 | -- |
内部人交易
| 日期 | 股东名称 | 变动股数(万股) | 交易后持股数量(万股) | 交易价格 | 是否直接持有 | 内部人类型 |
|---|---|---|---|---|---|---|
| 2025-12-31 | New Enterprise Associates 16, L.P. |
|
1227.33 | 1.37 | 是 | -- |
| 2025-12-02 | Galletta Christopher |
|
2.61 | 0.51 | 是 | Controller and Principal Accounting Officer |
| 2025-03-25 | SCIASCIA THOMAS |
|
22.40 | 1.43 | 是 | Chief Scientific Officer |
| 2025-03-25 | SCIASCIA THOMAS |
|
22.14 | 6.60 | 是 | Chief Scientific Officer |
| 2025-03-21 | GOOD JENNIFER L |
|
21.86 | 1.43 | 是 | President & CEO |
| 2025-03-21 | GOOD JENNIFER L |
|
21.33 | 6.58 | 是 | President & CEO |
| 2025-03-10 | Simon Farrell |
|
6.32 | 3.21 | 是 | Chief Commercial Officer |
| 2025-03-10 | Simon Farrell |
|
12.70 | 3.91 | 是 | Chief Commercial Officer |
| 2025-03-10 | Simon Farrell |
|
15.82 | 0.51 | 是 | Chief Commercial Officer |
| 2025-03-10 | Simon Farrell |
|
8.13 | 6.73 | 是 | Chief Commercial Officer |
| 2025-03-10 | Simon Farrell |
|
7.69 | 7.15 | 是 | Chief Commercial Officer |
| 2025-01-07 | Delfini Lisa |
|
6.47 | 0.51 | 是 | Chief Financial Officer |
| 2025-01-07 | Delfini Lisa |
|
5.97 | 0.51 | 是 | Chief Financial Officer |
| 2024-12-13 | Galletta Christopher |
|
1.99 | 0.51 | 是 | Controller and Principal Accounting Officer |
| 2024-09-06 | GOOD JENNIFER L |
|
21.75 | 1.43 | 是 | President & CEO |
| 2024-09-06 | GOOD JENNIFER L |
|
21.33 | 3.03 | 是 | President & CEO |
| 2024-09-06 | GOOD JENNIFER L |
|
21.52 | 1.43 | 是 | President & CEO |
| 2024-09-06 | GOOD JENNIFER L |
|
21.33 | 3.04 | 是 | President & CEO |
| 2024-09-03 | GOOD JENNIFER L |
|
21.72 | 1.43 | 是 | President & CEO |
| 2024-09-03 | GOOD JENNIFER L |
|
21.33 | 3.02 | 是 | President & CEO |
| 2024-09-03 | GOOD JENNIFER L |
|
22.43 | 1.43 | 是 | President & CEO |
| 2024-09-03 | GOOD JENNIFER L |
|
21.33 | 3.02 | 是 | President & CEO |
| 2024-09-03 | GOOD JENNIFER L |
|
25.36 | 1.43 | 是 | President & CEO |
| 2024-09-03 | GOOD JENNIFER L |
|
21.33 | 3.11 | 是 | President & CEO |
| 2024-08-27 | Meeker David P |
|
35.70 | 1.43 | 是 | -- |
| 2024-08-27 | Meeker David P |
|
35.25 | 2.93 | 是 | -- |
| 2024-08-19 | SCIASCIA THOMAS |
|
23.68 | 1.43 | 是 | Chief Scientific Officer |
| 2024-08-19 | SCIASCIA THOMAS |
|
22.03 | 2.96 | 是 | Chief Scientific Officer |
| 2024-08-14 | SCIASCIA THOMAS |
|
23.31 | 1.43 | 是 | Chief Scientific Officer |
| 2024-08-14 | SCIASCIA THOMAS |
|
22.04 | 1.43 | 是 | Chief Scientific Officer |
| 2024-08-14 | SCIASCIA THOMAS |
|
22.03 | 2.75 | 是 | Chief Scientific Officer |
| 2024-08-14 | SCIASCIA THOMAS |
|
22.03 | 2.79 | 是 | Chief Scientific Officer |
| 2024-08-14 | SCIASCIA THOMAS |
|
23.90 | 1.43 | 是 | Chief Scientific Officer |
| 2024-08-14 | SCIASCIA THOMAS |
|
22.03 | 2.76 | 是 | Chief Scientific Officer |
| 2024-05-29 | SCIASCIA THOMAS |
|
26.78 | 2.19 | 是 | Chief Scientific Officer |
| 2024-05-29 | SCIASCIA THOMAS |
|
21.44 | 2.55 | 是 | Chief Scientific Officer |
| 2024-05-22 | Delfini Lisa |
|
5.76 | 0.51 | 是 | Chief Financial Officer |
| 2024-05-22 | Delfini Lisa |
|
5.33 | 2.64 | 是 | Chief Financial Officer |
| 2024-05-20 | GOOD JENNIFER L |
|
23.84 | 2.19 | 是 | President & CEO |
| 2024-05-20 | GOOD JENNIFER L |
|
21.33 | 2.86 | 是 | President & CEO |
| 2024-05-10 | GOOD JENNIFER L |
|
21.79 | 2.19 | 是 | President & CEO |
| 2024-05-10 | GOOD JENNIFER L |
|
21.33 | 2.90 | 是 | President & CEO |